Olink — Scalable, multiplexed biomarkers

Rules-Based Medicine — a leader in testing soluble proteins for 25 years — performs Olink testing to support efficiency and precision in your clinical trials. 

Olink’s proximity extension assay (PEA^®) technology delivers the throughput you need without compromising specificity or scalability.

Whether you need a small panel of focused biomarkers or a comprehensive exploratory assessment, RBM has an Olink option to meet your needs.

The Olink PEA technology employs a dual-recognition approach using antibody pairs labeled with complementary DNA oligonucleotides. 

When the antibody pair binds to the target protein, the oligonucleotides are brought into proximity and hybridize, creating a unique DNA barcode for each protein.

This DNA barcode is then extended and amplified by polymerase chain reaction (PCR) and measured by quantitative PCR (qPCR) or next-generation sequencing (NGS).

Evaluate therapeutic effects

Accurately measure at baseline and after treatment to understand the dynamic changes associated with a therapeutic candidate.

Understand disease onset and mechanism of action

Certain biomarkers are present years before diagnosis. Olink can help identify the relevant proteomic changes.

Develop biomarker signatures

Explore HT measures thousands of proteins at once. Longitudinal studies can help you understand proteomic profiles for different diseases.

Identify drug targets

Disease-specific proteomic signatures can help identify potential drug targets.

Explore HT

Target 48

Carefully selected biomarkers for a comprehensive view: 

• Cytokine 
• Immune Surveillance 
  

Target 96

Biomarkers targeting specific therapeutic areas: 

• Cardiovascular II, Cardiovascular III 
• Oncology II, Immuno-Oncology, Immune Response 
• Neurology, Neuro Exploratory 
• Inflammation, Metabolism, Mouse Exploratory 

Service excellence

• RBM is an Olink service provider 
• Responsive client services team 
• My Green Lab® – bronze certification 
• Hands-on project managers who have experience working in the lab 
• 20+ years of expertise in delivering high-quality results on a timeline that meets your requirements. 

Exceptional Science

• Dual-recognition approach uses antibody pairs labeled with DNA oligonucleotides 
• Hybridization creates a unique barcode that is amplified using PCR 
• Readouts by qPCR or NGS based on platform 

Meaningful insights

Disease-specific insights: 

• Oncology 
• Inflammation/Immunology 
• Cardiovascular 

Broad biosignatures (Explore HT) 

• Deeper understanding of biological pathways and multi-omics interactions 
• Scalable without compromising quality